Abstracts tagged "Cardiovascular disease"

Abstract Number: 213 • 2018 ACR/ARHP Annual Meeting
Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease
Annette de Thurah^1,2, Ina Trolle Andersen³, Andreas Bugge Tingaard⁴, Josephine Therkildsen⁵, Anders Hammerich Riis³, Morten Böttcher⁵ and Ellen-Margrethe Hauge^6,7, ¹Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁵Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after…
Abstract Number: 513 • 2018 ACR/ARHP Annual Meeting
Low Serum IGF1 Is Associated with Higher Cardiovascular Morbidity in the Middle-Aged Women with Rheumatoid Arthritis
Malin C Erlandsson^1,2, Lovisa Lyngfelt³, Caroline Wasén³, Sofia Töyrä Silfverswärd³, Mitra Nadali^1,3, Rille Pullerits^1,3,4 and Maria I Bokarewa¹, ¹Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, ³Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ⁴Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Background/Purpose: Since low serum IGF1 is generally attributed to inflammation and RA severity, we analyze if serum levels of IGF1 is associated with cardiovascular (CV)…
Abstract Number: 958 • 2018 ACR/ARHP Annual Meeting
Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting
Fenglong Xie¹, Huifeng Yun¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Multiple studies have observed unfavorable changes in lipid profile associated with tocilizumab (TCZ, anti-IL6 receptor antagonists) and some other rheumatoid arthritis (RA) therapies. The…
Abstract Number: 1634 • 2018 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results of a National Study
Cristina Fernández-Carballido¹, Maria Auxiliadora Martin², María Carmen García-Gómez³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, Rosario García-Vicuña⁷, Celia Erausquin⁸, Francisco J Lopez-Longo⁹, María D Sanchez-Gonzalez¹⁰, Alfonso Corrales¹¹, Estefania Quesda-Masachs¹², Eugenio Chamizo Carmona¹³, Carmen Barbadillo¹⁴, Javier Bachiller¹⁵, Tatiana Cobo-Ibáñez¹⁶, Ana Turrión Nieves¹⁷, Emilio Giner Serret¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay¹¹, ¹Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁴Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁸Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ⁹Rheumatology Department, Hospital Gregorio Marañón, Madrid, Spain, ¹⁰Rheumatology, Hospital Clínico, Salamanca, Spain, ¹¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Rheumatology Division, Hospital Vall Hebrón, Barcelona, Spain, ¹³Rheumatology, Hospital de Mérida, Merida, Spain, ¹⁴Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁵Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ¹⁶Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de Salamanca. Spain, Salamanca, Spain, ¹⁸Rheumatology, H Obispo Polanco, Teruel, Spain, ¹⁹Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain
Background/Purpose: Functional status gets worse with comorbidities regardless of disease activity in patients with rheumatoid arthritis (RA). However, the impact of comorbidities on physical function…
Abstract Number: 2243 • 2018 ACR/ARHP Annual Meeting
Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults
Angelo Gaffo¹, Elizabeth J. Rahn², Tanja Dudenbostel¹, Amy S. Mudano¹, Peng Li³, David T. Redden³, Stephanie Biggers¹, Phillip J. Foster², Paul M. Muntner⁴, Suzanne Oparil⁵, David A. Calhoun⁵ and Kenneth Saag¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Serum urate (sUA) has been associated with blood pressure in most but not all studies. This study aims to test whether there are sex…
Abstract Number: 301 • 2018 ACR/ARHP Annual Meeting
Rheumatology Clinic Staff Needs for Partnering to Improve Blood Pressure and Tobacco Risk Management
Michelle Tong¹, Laura Block², Andrea Gilmore-Bykovskyi², Edmond Ramly³ and Christie M. Bartels⁴, ¹Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, ²University of Wisconsin School of Nursing, Madison, WI, ³Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Patients with rheumatologic conditions are at a higher risk of cardiovascular disease (CVD) than peers. High blood pressure (BP) and tobacco use exacerbate CVD…
Abstract Number: 514 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Risk Management in Seropositive Rheumatoid Arthritis: What Can We Do Better?
Matthew McElwee¹, Peter Boersma², Hiba Hashmi³ and Anna K. Shmagel¹, ¹Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ²School of Public Health, University of Minnesota, Minneapolis, MN, ³School of Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: The increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA) has been well established. While the reasons for an increased risk of CVD…
Abstract Number: 1070 • 2018 ACR/ARHP Annual Meeting
Seroreactivity Against Recombinant Citrullinated Myosin Is Associated with Measures of Diastolic Dysfunction in Patients with Rheumatoid Arthritis
Christian Geier¹, Justyna Fert-Bober², Jon T. Giles¹, Cesare Russo¹, Sabahat Bokhari³, Aylin Tugcu¹, Jenny Van Eyk² and Joan Bathon¹, ¹Columbia University, New York, NY, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Cardiology, Columbia University, New York, NY
Background/Purpose: Diastolic dysfunction and heart failure with preserved EF are more prevalent in RA. We have previously shown increased staining for citrullinated substrates in necropsied…
Abstract Number: 1650 • 2018 ACR/ARHP Annual Meeting
Subclinical Atheromatosis and Estimation of Cardiovascular Risk in Patients with Axial Spondyloarthritis
Tomas Cazenave¹, Maria Celeste Orozco², Gustavo Citera³, Emilce E Schneeberger¹ and Marcos G. Rosemffet², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina
Background/Purpose: There is evidence that shows an increased cardiovascular risk in patients with Axial Spondyloarthritis (axSpA). Ultrasonography (US) is a simple imaging tool used to…
Abstract Number: 2354 • 2018 ACR/ARHP Annual Meeting
Perspectives of Patients with Inflammatory Arthritis Regarding Cardiovascular Risk: A Qualitative Study
Iris Navarro-Millán^1,2, Sarah Young³, Sally Shurbaji⁴, Chastity McDavid⁴, Anna Cornelius-Schecter², Bernadette Johnson⁴, Andrea Cherrington⁴, Liana Fraenkel⁵, Jeffrey R. Curtis⁴ and Monika M. Safford², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Binghamton University, Binghamton, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Yale University, New Haven, CT
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with inflammatory arthritis (IA) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
Abstract Number: 338 • 2018 ACR/ARHP Annual Meeting
Implementation of an Automated Phrase to Increase Awareness of Cardiovascular Risk in Rheumatoid Arthritis Patients in an Urban Fellows Rheumatology Clinic
Leslie Anne Cassidy¹, Jennifer Brandt¹, Alison Gizinski², Arezou Khosroshahi¹, Gaobin Bao¹ and S. Sam Lim³, ¹Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Rheumatoid arthritis (RA) is a significant and well-established risk factor for atherosclerotic cardiovascular disease (ASCVD). Cardiovascular risk stratification is often left to the primary…
Abstract Number: 515 • 2018 ACR/ARHP Annual Meeting
How Knowledgeable Are Patients with Rheumatoid Arthritis about Cardiovascular Disease?
Meenakshi Jolly¹, Aman Kugasia², Salik Hussaini², Joshlean Fair³, Mondira Sengupta⁴, Lisa Walt⁵, Rasa Kazkauskaite⁶ and Joel A. Block³, ¹Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴John H Stroger Hospital of Cook County, Chicago, IL, ⁵American Hospital Association, Chicago, IL, ⁶Rush University, chicago, IL
Background/Purpose: Despite dramatic change in treatment options in recent years, cardiovascular disease (CVD) mortality has not improved in rheumatoid arthritis (RA) and remains the leading…
Abstract Number: 1071 • 2018 ACR/ARHP Annual Meeting
Protective Role of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Rs2495477 Polymorphism in Patients with Rheumatoid Arthritis
Sara Remuzgo-Martínez¹, Fernanda Genre¹, Verónica Pulito-Cueto¹, Alfonso Corrales¹, Javier Llorca², Verónica Mijares¹, Leticia Lera-Gómez¹, Virginia Portilla¹, Iván Ferraz-Amaro³, Santos Castañeda⁴, Oreste Gualillo⁵, Javier Martín⁶, Ricardo Blanco¹, Raquel Lopez-Mejías¹ and Miguel Angel González-Gay⁷, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain, ⁴Rheumatology Department, Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁶Instituto de Parasitología y Biomedicina "López-Neyra", CSIC, PTS Granada, Granada, Spain, Granada, Spain, ⁷Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: RA is associated with the development of cardiovascular (CV) disease and subclinical atherosclerosis, which leads to an increased risk of CV mortality in RA…
Abstract Number: 1729 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Valvular Heart Disease in Patients with Systemic Sclerosis: Results from a Population-Based Cohort (1980-2016)
Reto Kurmann¹, Avneek Singh Sandhu², Cynthia S. Crowson³, Rekha Mankad¹, Thomas Osborn², Kenneth J. Warrington⁴ and Ashima Makol², ¹Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogenous autoimmune disease characterized by microvascular injury and widespread fibrosis of the skin and internal organs, particularly lungs…
Abstract Number: 2498 • 2018 ACR/ARHP Annual Meeting
The Association of Vitamin D with the Lipid Profile in Rheumatoid Arthritis: An Interplay Among Genetic Polymorphisms, DHCR7 Levels and Seasonality
Javier Rodríguez-Carrio^1,2,3, Mercedes Alperi-López⁴, Manuel Naves-Díaz^2,3, Adriana Dusso^2,3, Patricia López¹, Francisco Javier Ballina-García⁵, Jorge B. Cannata-Andía^2,3 and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain, ³Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain, ⁴Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁵Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose: Vitamin D deficiency is a common hallmark of rheumatic diseases, and some controversy exists about its effect on rheumatoid arthritis (RA), in particular about…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].